Fidson profit rises 47% as financing and currency costs ease

Fidson Healthcare increased nine-month profit after tax to N11.74 billion from N7.97 billion as revenue growth, lower financing charges and a sharply smaller foreign-exchange loss strengthened its earnings. The pharmaceutical manufacturer's accounts were filed in the NGX disclosure stream on 28 October, covering the period ended 30 September 2026.

The result points to stronger profitability, but also to a business carrying substantially more inventory and customer balances. The distinction matters for assessing how much of the earnings improvement can support further production without additional funding.

Revenue growth comes with a stronger gross margin

According to Fidson's unaudited financial statement , revenue rose to N112.61 billion from N93.08 billion. Gross profit increased to N48.94 billion from N38.21 billion.

BusinessPress calculations put the gross margin at approximately 43.5%, against 41.1% a year earlier. That means the company retained more of each naira of sales before administrative, distribution and financing expenses. It is a more useful indicator of the trading improvement than revenue growth viewed in isolation.

The accounts do not, through those aggregate numbers alone, establish the separate contribution of price increases and physical sales volumes. The increase should therefore not be described as an equivalent expansion in medicine consumption or factory output. Product mix and input costs can change the margin even when volume growth differs from revenue growth.

Financing and currency relief support the profit increase

Finance costs fell to N3.73 billion from N5.14 billion, while the net exchange loss narrowed to N104 million from N4.16 billion. Operating profit reached N21.24 billion, against N16.95 billion.

Those movements show why a profit growth rate can exceed the growth in sales. Less income was absorbed by financing, while the currency-related drag was much smaller. This is an improvement in the reported period, but it should not automatically be projected into the next one.

A currency loss can reflect the timing and settlement of obligations as well as exchange rates. Similarly, a reduction in interest expense is not proof that borrowing has disappeared. The appropriate assessment separates improved operating margins from relief in financial charges, rather than treating all additional profit as a permanent efficiency gain.

Stock and receivables absorb a larger pool of resources

Inventories increased to N36.96 billion from N26.55 billion at December 2025. Trade and other receivables rose to N29.32 billion from N11.07 billion, while trade and other payables reached N30.35 billion from N6.63 billion.

These are comparisons with the year-end balance sheet, rather than with September of the previous year. They cannot be presented as year-on-year movements. They nevertheless show that the scale of resources tied to the operating cycle increased during 2026.

Inventory can provide supply resilience, but it must eventually convert into saleable products. Receivables support distribution where customers purchase on credit, but recognised sales become useful funding only when collected. Supplier credit can finance part of that cycle, although payment deadlines remain obligations. The three balances need to be read together.

Equity funding changes the denominator for shareholders

Fidson reported equity of N60.01 billion and issued share capital of N1.50 billion, compared with N30.20 billion and N1.20 billion respectively at year-end. Its statement of changes in equity records additional shares and share premium.

New equity can reduce dependence on short-term borrowing and provide resources for expansion. For an existing shareholder, however, a larger share base also changes how total profit translates into earnings per share. Growth in the company's aggregate earnings is not interchangeable with growth in each investor's economic claim.

That is why comparisons should use the issuer's per-share disclosures and their stated basis, rather than divide a headline profit by an assumed historical share count. The funding benefit and the ownership effect are both relevant to evaluating the transaction.

Expansion raises a collection test for the next reporting period

The reporting period ended in September and the board signed the accounts on 22 October; their later disclosure is the fresh information event. These are interim unaudited figures, rather than a new full-year forecast.

For Nigeria's pharmaceutical value chain, the result offers evidence of a larger and more profitable listed manufacturer. It does not establish that industry-wide shortages, import exposure or affordability constraints have been resolved. The next useful test is whether the larger operating base produces sustained collections and margins as stock is sold and outstanding customer balances fall due.